Singapore approves Bavarian's mpox vaccine Jynneos

COPENHAGEN (Reuters) - Danish biotech Bavarian Nordic said on Tuesday its mpox vaccine Jynneos had been approved by Singapore's medicines regulatory authority for use in the country.

The vaccine was approved to prevent smallpox and mpox in individuals at the age of 18 or older who are determined to be at high risk for the disease, marking the transition to a full approval for Jynneos in Singapore, Bavarian said in a statement.

(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)